Please ensure Javascript is enabled for purposes of website accessibility

Here's Why MannKind Corporation Stock Is Tanking Today

By George Budwell – Updated Apr 6, 2018 at 7:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind taps investors for some much-needed capital.

What happened

Shares of MannKind Corporation (NASDAQ: MNKD), the maker of inhaled insulin product Afrezza, are down by 15.3% in pre-market trading today on heavy volume.

The drugmaker's shares are responding negatively to a planned direct offering of 14,000,000 shares of common stock and warrants for a combined purchase price of $2.00. MannKind will reportedly receive $28 million in gross proceeds once the offering is complete. 

A man in business attire looking at a tablet with a negative trending graph illustrated above it.

Image Source: Getty Images.

So what

The main reason MannKind's shares are tanking this morning is because the offering comes at a 15% discount relative to the stock's closing price yesterday. In other words, the company probably had to price the offering at a substantial discount simply to entice these "select institutional investors."

Now what

Last month, I warned investors that another sizable capital raise was imminent, and sure enough, MannKind followed through as predicted. The brutal truth is that MannKind's inhaled insulin endeavor has failed, leaving the company no available options but to continue diluting shareholders on a regular basis just to keep its doors open.

Given this never-ending cycle of diluting shareholders, the biotech's shares will almost certainly fall below the $1 minimum bid requirement for the Nasdaq stock exchange before year's end -- thereby forcing MannKind to execute another value-destroying reverse split in the near future. That is, unless the biotech's management finally decides to throw in the towel and declare bankruptcy in the interim. 

While it's tempting to think Afrezza can make a comeback, there's no real-world evidence that such a dramatic turnaround is taking place. To be fair, Afrezza's scripts have been improving modestly in recent months, but not at the rate required to avoid capital raises every few months. As such, I think investors are best served by avoiding this falling knife altogether. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.